Low-dose testosterone undecanoate capsules combined with tadalafil for late-onset hypogonadism accompanied with ED

• Published in: Zhonghua nan ke xue Vol. 19; no. 7; p. 630
• Main Authors: Li, Guang-Yu, Liang, Ji-Hong, Meng, Zhi-Bin, Huang, Cun-Chao, Liang, Shi-Kun, Wei, Guo-Qiang, Shen, Shu-Lin, Zhu, Chun-Hui, Zhang, Xun, Song, Wei-Ru
• Format: Journal Article
• Language: Chinese
• Published: China 01.07.2013
• Subjects: Adult; Carbolines - administration & dosage; Carbolines - therapeutic use; Drug Therapy, Combination; Erectile Dysfunction - complications; Erectile Dysfunction - drug therapy; Humans; Hypogonadism - complications; Hypogonadism - drug therapy; Male; Middle Aged; Tadalafil; Testosterone - administration & dosage; Testosterone - analogs & derivatives; Testosterone - therapeutic use; Treatment Outcome
• ISSN: 1009-3591

To observe the clinical effect of low-dose testosterone undecanoate capsules combined with tadalafil on late-onset hypogonadism (LOH) accompanied with ED. Ninety cases of LOH accompanied with ED who met the inclusion criteria were randomly divided into a control group and a combination therapy group, the former treated with tadalafil and the latter with low-dose testosterone undecanoate capsules combined with tadalafil. The LOH symptoms, IIEF-5 scores, sexual encounter profile (SEP) scores, prostate volumes, and the levels of total testosterone (TT), free testosterone (FT) and prostatic specific antigen (PSA) were recorded and compared between the two groups before and after treatment. The IIEF-5 and SEP scores and the TT and FT levels were 20.6 +/- 3.8, 4.02 +/- 1.08, (15.4 +/- 3.4) nmol/L and (0.391 +/- 0.062) nmol/L, respectively, in the combination therapy group after treatment, significantly higher both than 15.7 +/- 3.9, 1.49 +/- 0.82, (10.1 +/- 1.2) nmol/L and (0.200 +/- 0.045) nmol/L before treatment